SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (ticker: BCYP) filed an 8-K with the Securities and Exchange Commission on June 27, 2024. The company reached its current public status through a business combination with Big Cypress Acquisition Corp, a blank-check vehicle that completed its initial public offering in 2021. SAB Biotherapeutics operates in the clinical-stage biopharmaceutical sector, with a pipeline centered on human polyclonal antibody therapeutics produced using genetically engineered cattle. The combined entity has been publicly traded since the de-SPAC transaction closed in late 2022. Investors and analysts tracking post-merger SPAC companies in the biotechnology space can access full filing histories, sponsor details, and deal analytics for BCYP by signing up for complete data on SpacDesk.